Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Clin Cancer Res. 2023 Sep 1;29(17):3329–3339. doi: 10.1158/1078-0432.CCR-23-0709

Figure 1:

Figure 1:

Swimmer plot depicting summary of treatment duration in cycles, timing of dose-limiting toxicities (DLT) (red), and clinical outcomes of partial reponse (PR) (yellow) and progressive disease (PD) (green) for patients treated at dose level 1 (light blue) and dose level 2 (dark blue).